ClinicalTrials.gg
CompletedNCT06902337MaGenUpdated Oct 5, 2026

Gender Differences in Gastric Cancer Care and Its Adherence to Guidelines in Germany

An observational study in Gastric Adenocarcinoma, sponsored by Medizinische Hochschule Brandenburg Theodor Fontane. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Medizinische Hochschule Brandenburg Theodor Fontane · Observational

How we know

Updated Oct 5, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
75,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Stomach Neoplasms with a site in Germany — 26 open to participants now, 42 under way, 13 of them phase 3. Stomach Neoplasms · Germany.

Enrollment
Largest of 23
75,000 · median 300
Started
2025
with 10 others
Observational
23 of 162
4 open now
Registered
151st of 162
by date

Among the 162 studies in Stomach Neoplasms with a site in Germany, this one has the largest enrollment of the 23 observational ones that give a count, is one of 11 that started in 2025, is one of 23 observational ones, and was the 151st registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

26 of the 162 studies in Stomach Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Stomach Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

Background: Gastric cancer is the fifth most common cancer globally and the fourth leading cause of cancer-related mortality. While gender differences in gastric cancer care are underexplored in Germany, international studies have revealed disparities in aspects such as histology, co-morbidities, treatment approaches, and survival outcomes. This study aims to explore gender-specific variations in clinical management and their impact on mortality, complications, and survival rates in gastric carcinoma patients in Germany.

Methods: This nationwide, retrospective cohort study will analyze data from the German Diagnosis-Related Group statistic and regional clinical cancer registries from 2017 to 2021. The study will evaluate both datasets separately, providing a comprehensive view of gender differences in gastric cancer care. Primary outcomes include hospital mortality and survival rates, while secondary endpoints include surgical complications, treatment modalities, and postoperative outcomes. The analysis will investigate whether gender influences tumor characteristics, access to treatment, and therapy effectiveness. Statistical methods such as descriptive analysis, regression models, and survival analysis will be applied to identify gender-related variations in diagnosis, treatment, and outcomes.

Discussion: By identifying potential gender disparities in diagnosis, treatment, and outcomes, the findings may inform revisions to clinical guidelines and support the development of more personalized treatment strategies. This study aims to improve the quality of care for gastric cancer patients and promote more individualized, sex-sensitive medical practices.

Read the detailed description

Gastric cancer is the fifth most common cancer globally and the fourth leading cause of cancer-related mortality. While there is a lack of current data on gender differences in gastric cancer care in Germany, several international studies conducted on the basis of clinical cancer registry data have pointed to the relevance of this aspect in recent years. The analyses showed significant differences between women and men in aspects such as histology, co-morbidities, operations and therapies performed, and survival rates.

In Germany in 2017, 15,690 people were diagnosed with gastric cancer, of which 6190 were women (39%) and 9490 men (61%). The age-standardized rate of new cases is 7.8 for women and 14.9 for men. The risk of developing the disease increases with age in both sexes; men develop stomach cancer on average at the age of 71 and women at 76 years of age. There are regional differences between the federal states of Germany in all key figures. For example, in the state of Bavaria in 2019, both sexes have an above-average 5-year survival rate of 46.1% for men and 50.7% for women, while in the state of Brandenburg there is a large difference in this ratio between men (38.5%) and women (46.0%).

With regard to hospital mortality in Germany, an analysis of data from the DRG statistics for the years 2009 -2015 showed that the highest mortality rate of 11.7% was observed in patients undergoing visceral surgery in complex gastric surgery (in comparison, average hospital mortality among patients undergoing visceral surgery: 1.9%).

The aim of the project is to use routine data of the DRG statistic and data from the clinical cancer registries of the federal states to determine whether there are differences between women and men in the clinical care of gastric carcinomas and whether such different care has an impact on the mortality rate, complications and survival time of those affected.

Data from the hospital statistics (DRG statistics) and data from the clinical cancer registries are used as the data basis for the above-mentioned research questions and evaluated separately from each other.

In a first step, it will be investigated whether and to what extent women and men already differ in tumor characteristics (diagnosis, localization, histology, UICC stage, etc.) and in possible co-morbidities and co-variates such as age.

In a second step, the therapy (surgical procedures, oncological therapies) is analyzed under the focus variable gender. The aim here is to analyze whether women and men receive the same therapies if, for example, the tumor characteristics have the same tumor characteristics, or whether there are differences in both access and type of therapies.

In a third step, both the influence of the tumor characteristics and the therapies used on the outcome of the therapies will be investigated under gender-specific aspects. These include, for example, complications after surgery, side effects of oncological therapies, length of hospital stay, hospital mortality or long-term survival. It is of particular interest here whether there are particularly successful therapeutic strategies depending on gender and diagnosis with regard to the above-mentioned outcome parameters, i.e. whether there is a need to treat women and men differently if, for example, the tumor characteristics have the same tumor characteristics.

Since both analyses complement each other in their statements, the project can thus provide a comprehensive picture of gender-specific care in Germany. Furthermore, the project results provide a scientific data basis for a possible revision of the S3 guideline for the treatment of gastric cancer as well as for medical education and training.

03

Conditions studied

  • Gastric Adenocarcinoma

Browse trials for

Keywords

  • Gastric cancer
  • Sex differences
  • Clinicopathological characteristics
  • Treatment
  • Mortality
  • Survival
  • Treatment guidelines
  • Administrative routine data
  • Cancer registry data
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A) Cases from the DRG statistics for the years 2017-2021 with inclusion criteria minimum age 18 years, full inpatient hospital treatment in the years 2017-2021, ICD-10-GM code C16, C16.1 - C16.9 B) Cases recorded in a clinical cancer registry from 2017-2021 with ICD-10-GM code C16, C16.1-C16.9

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Gastric adenocarcinoma ICD-10-GM code C16, C16.1 - C16.9

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
75,000 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with gastric adenocarcinoma

    Gastric carcinoma (ICD-10-GM C16) Patients with gastric carcinoma in the years 2017-2021 in Germany, minimum age 18 years

06

What researchers measure

Primary outcomes

  1. DRG statistic: in-hospital mortality

    Death in hospital after treatment in days

    Time frame: 2017-2021

  2. Cancer registry: 1 and 3 year survival

    Survival after diagnosis date in months

    Time frame: 2017-2021

07

Study locations

1 site
  • Medical School Brandenburg
    Brandenburg an der Havel, Brandenburg 14770, Germany
08

References and documents

Publications

  • Weber U, Kress L, Hunger R, Schildberg C, Mantke R. Gender differences in gastric cancer care and its adherence to guidelines in Germany (MaGen): protocol for an observational retrospective cohort study with administrative routine and cancer registry data from 2017 to 2021. BMJ Open. 2026 Feb 2;16(2):e103467. doi: 10.1136/bmjopen-2025-103467. PubMed 41628928 ↗

Individual participant data

Plan to share: No — Due to data protection

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2025 to primary completion in Jul 2026, 11 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Apr 2026 → Jul 2026 and completion Apr 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2025
First posted
Mar 30, 2025
StartActual
Jul 31, 2025
Primary completionActual
Jul 30, 2026was Apr 2026
CompletionActual
Jul 30, 2026was Apr 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 5, 2026
Primary completion
Apr 30, 2026→Jul 30, 2026 (actual)
Oct 5, 2026
Study completion
Apr 30, 2026→Jul 30, 2026 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Active, not recruiting→Completed
    Primary completion Apr 30, 2026→Jul 30, 2026 (now actual)
    Study completion Apr 30, 2026→Jul 30, 2026 (now actual)
    + 1 other change: oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06902337
Lead sponsor
Medizinische Hochschule Brandenburg Theodor Fontane
Responsible party
Rene Mantke (MD, PhD, Head of Surgery at University Hospital Brandenburg an der Havel, Medizinische Hochschule Brandenburg Theodor Fontane) — Principal investigator
First posted
Mar 30, 2025
Start date
Jul 31, 2025
Primary completion
Jul 30, 2026
Completion
Jul 30, 2026
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion